COLUMBIA, Md., June 3 /PRNewswire-FirstCall/ -- Martek
Biosciences Corporation (Nasdaq: MATK) announced today that it has
entered into a multi-year DHA and ARA agreement with Feihe Dairy, a
wholly owned subsidiary of American Dairy, Inc. Under the
terms of the agreement, Feihe Dairy will purchase its total
requirements of DHA and ARA for its new premium infant formula and
growing-up milk products sold in China.
"This new agreement with Feihe Dairy is another important step
in Martek's effort to expand its international presence in the
Chinese infant formula market," said Binglin Shen, general manager of China operations for Martek. "We are pleased
to be working with Feihe Dairy and believe this agreement again
demonstrates that companies around the world continue to recognize
the importance of adding Martek's trusted sources of DHA and ARA to
products for infants and children."
"Featuring life'sDHA and life'sARA, Xinfeifan Baby
Formula Milk Powder is designed to meet the nutritional
requirements of child growth and development," said You-bin Leng,
Feihe Dairy chairman and CEO. "Feihe Diary is pleased to partner
with Martek to launch this innovative, quality infant formula
product that is important to Feihe Dairy's international
strategy."
Martek manufactures nutritional oils that contain the long-chain
polyunsaturated fatty acids DHA and ARA, both of which are
naturally present in breast milk. Clinical studies have
demonstrated benefits for infants receiving formula supplemented
with DHA and ARA. Martek's proprietary blend of DHA and ARA,
marketed under the brand names life'sDHA and
life'sARA™, is currently used in over 95 percent of U.S.
infant formulas. Additionally, infant formula containing
life'sDHA and life'sARA has been consumed by over 50
million infants in over 75 countries worldwide.
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the
innovation, development, production and sales of high-value
products from microbial sources that promote health and wellness
through nutrition. The company is the world's leading
provider of algal DHA omega-3 with its flagship product,
life'sDHA, a sustainable and vegetarian source of algal DHA
omega-3 important for brain, heart and eye health throughout life,
for use in foods, beverages, infant formula, and supplements. The
company also produces life'sARA™ (arachidonic acid), an
omega-6 fatty acid, for use in infant formula and growing up milks.
Additionally, Martek's subsidiary, Amerifit Brands, develops,
markets and distributes branded consumer health and wellness
products in major mass, club, drug, grocery and specialty stores
and holds leading brand positions in all of its key product
categories. For more information on Martek Biosciences, visit
www.martek.com/. For a complete list of life'sDHA™ or
life'sARA™ products, visit www.lifesdha.com or
www.lifesdha.cn/. For more information about Amerifit Brands, visit
www.amerifit.com.
Sections of this release contain forward-looking statements.
These statements are based upon numerous assumptions which Martek
cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in
light of the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not limited
to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
|
|
|
|
Cassie France-Kelly
|
|
Public Relations
|
|
(443) 542-2116
|
|
media@martek.com
|
|
|
|
Kyle Stults
|
|
Investor Relations
|
|
(410) 740-0081
|
|
investors@martek.com
|
|
|
SOURCE Martek Biosciences Corporation